Pablo Domizi

Employment

• Stanford University Senior Research Scientist
  2025 - Present
• Stanford University Instructor
  2021 - 2025
• Stanford University Postdoctoral fellow
  2018 - 2021

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (38)

• DHODH as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.
  Blood 2026 DOI: 10.1182/blood.2025029264
  +Save
• Training Tomorrow's Leaders in Cancer Immunology.
  Cancer immunology research 2026 DOI: 10.1158/2326-6066.CIR-25-1479
  +Save
• CellFuse Enables Multimodal Integration of Single-Cell and Spatial Proteomics Data for Systems-Level Analysis in Cancer
  Cancer Research 2026 DOI: 10.1158/0008-5472.CAN-25-3699
  +Save
• Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results
  2025 DOI: 10.1182/blood-2025-2374
  +Save
• Multi-omic analysis of early minimal residual disease identifies functional and transcriptomic signatures of treatment resistance in pediatric B-cell acute lymphoblastic leukemia
  2025 DOI: 10.1182/blood-2025-334
  +Save
• Annotation-Free Discovery of Disease-Relevant Cells in Single-Cell Datasets
  Science Advances 2025 DOI: 10.1126/sciadv.adv5019
  +Save
• A genome-wide, CRISPR-based screen reveals new requirements for translation initiation and ubiquitination in driving adipogenic fate change.
  Genes & development 2025 DOI: 10.1101/gad.352779.125
  +Save
• IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies
  Nature Communications 2025 DOI: 10.1038/s41467-025-58868-2
  +Save
• Uridine Metabolism as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.
  bioRxiv : the preprint server for biology 2025 DOI: 10.1101/2025.01.27.635108
  +Save
• IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia
  2024 DOI: 10.1101/2024.11.01.621347
  +Save